OneChain Immunotherapeutics

🌟 Our Work Continues 🔬 As summer unfolds, we at OneChain Immunotherapeutics remain steadfast in our mission to revolutionize cancer treatment. Our research and development efforts are ongoing. 💊 We’re driving progress in our four active research programs, one of them on clinical phase, with a focus on advancing #CARTCellTherapies for acute lymphoblastic leukemia and pioneering γδ T-cell therapies. We're also exploring dual CAR T strategies to fight glioblastoma. 👩🔬 Even during this season of rest, our commitment to innovation in #CancerResearch is unwavering. Thank you for your continued support as we work toward a future where cancer is no longer a life-threatening diagnosis. 🙌 #Oncology #Biotech #Immunotherapy #Innovation

We are back from the excellent Gamma Delta T Therapies Summit in Boston. 📊 Our CEO Stefanos Theoharis presented the latest data from our innovative GDT platform, based on the differentiation of Vδ1 gamma delta T-cells from stem cells, followed by a round table discussion led by Laura García Pérez, our senior scientist leading this work. Some key takeaways: 1️⃣ Our work met with very positive feedback and was recognised as a positive step forward for the field, contributing several advantages. 2️⃣ The field continues to grow as pipelines mature and companies release positive data from the lab and the clinic. 3️⃣ The superior anti-tumoral efficacy of GDTs is continuously being demonstrated by different groups, due to the cells’ innate specificity against tumour antigens and stress signals. There is still work needed to better understand this effect and harness it for further patient benefit. 👋🏻 We are looking forward to continuing to contribute to the effort of delivering better patient outcomes, and establishing OneChain as an important player in the space. See you all next year! Our thanks to the conference organisers, and our partners, the CSIC, iBET - Instituto de Biologia Experimental e Tecnológica and Josep Carreras Leukaemia Research Institute. The project funded by the European Union’s EIC Transition programme under Grant Agreement nº 101113067. 

Our CEO Stefanos Theoharis is attending the Gamma Delta T Therapies Summit! 🌟 It's inspiring to see our team's participation and hear about the advancements in GD T-cell therapy. Looking forward to the insights that will come from this event and to our team's intervention presenting our innovative GD T-cell platform, a work funded by European Innovation Council and SMEs Executive Agency (EISMEA), working together with the Centro de Biología Molecular Severo Ochoa, CBM and iBET - Instituto de Biologia Experimental e Tecnológica.

☀️ Last week, part of our team participated on the Catalonia.Health (CataloniaBio & HealthTech) BBQ! This networking event has become a must-attend in ourt agendas every summer, being a unique opportunity to connect with other entrepreneurs and professionals in the biomedicine and health sector. ✨  We are very grateful to the organisers for making this appointment possible for another year. #CataloniaBioHealthTech #Networking #Biomedicine #HealthSector

✨ Exciting Day at OneChain Immunotherapeutics! ✨ Yesterday, we had the honor of welcoming several distinguished guests to our laboratory at the Parc Científic de Barcelona: Jordi Valls Riera, Deputy Mayor of the Economic Area of the Ajuntament de Barcelona; Dr. Joan Guàrdia Olmos, Rector of the Universitat de Barcelona; Sr. Jordi Bosch de Borja, Deputy Manager of Strategic Projects at the University of Barcelona; and Sra. Maria Terrades Palomar, Director of the Barcelona Science Park. The visit took place as part of the BCN Health Booster initiative, a three-year program for companies in the health sector to be accelerated through access to a laboratory at the Barcelona Science Park and a specialised acceleration programme by Biocat, BioRegion of Catalonia. We are thankful and feel privileged to be a part of this important initiative and our gratitude goes to the Barcelona City Council, Barcelona Science Park, Barcelona Activa, and Biocat for their active support that we have enjoyed over the last three years 🙏 Special thanks to Jordi Valls, Joan Guàrdia, Jordi Bosch, and Maria Terrades for taking the time to visit and recognize the work we are doing at OneChain. Together, we are fostering innovation and making strides towards better healthcare solutions. 💡🔬 #BCNHealthBooster #HealthSector #PCBCommunity

We’ve reached 3,000 followers on LinkedIn! 🎉 Thank you to everyone who has supported us on this journey. Your engagement and encouragement drive us to continue pushing the boundaries of research and innovation to improve the lives of patients with oncological diseases. We are excited about the future and look forward to sharing more milestones, breakthroughs, and updates with you. Here’s to many more achievements together! Stay tuned and keep following us for more exciting news! #CARTCellTherapy  #Innovation #Oncology

🌟 We are thrilled to welcome Almudena to our team at #OneChain Immunotherapeutics! 🌟 With a background in Biology and extensive experience as a Research Technician in both Spain and the UK, Almudena brings a wealth of knowledge and expertise to our team. At OneChain, she will focus on advancing our developments with iPSCs, helping us lead the way in therapeutic #innovations. Her expertise will be invaluable in our ongoing commitment to research and development in the field of #immunotherapy. 🔗 Learn more about Almudena and the rest of our team by visiting our website https://lnkd.in/dMeN4BeX

🔬 We're thrilled to share an article from Fundación Botín that highlights our dedication to developing CAR T therapies and advancing cancer treatment innovations. 📜 The article delves into our origins, the potential of these innovative therapies, and reviews the significant progress of our ongoing projects. It also discusses the strategic financing that has been crucial in propelling these initiatives forward. We invite you to read the full article to gain a deeper understanding of our efforts to enhance the lives of cancer patients. A special thanks to Fundación Botín for helping to spread the word about our work. 🔗 https://lnkd.in/d7vEh6yX #CancerCare #Innovation #CARTTherapy

Today, we celebrate 4 years of OneChain Immunotherapeutics! 🎉 From our foundation in 2020 to the transformative advancements of 2024, we have tirelessly pursued innovative therapies to address unmet medical needs. Our mission is to develop better therapies for cancer patients in need. Today, we are excited to share our most significant milestones over the years. Join us on this journey through our key achievements and celebrate this anniversary filled with innovation and hope 🚀🔬 In addition, we want to thank our investors, partners, and the incredible #OneChain team for making this journey possible. The future of immunotherapy is promising, and we are excited to continue this path together! Invivo Partners, Fundación Josep Carreras contra la Leucemia, CDTI Innovación, Nara Capital, Clave Capital, Josep Carreras Leukaemia Research Institute, ICREA - Institució Catalana de Recerca i Estudis Avançats, Ajuntament de Barcelona, Barcelona Activa, CSIC, European Research Council (ERC), Biocat, BioRegion of Catalonia, Fundación Unoentrecienmil, Ministerio de Ciencia, Innovación y Universidades, Doctorats Industrials, Asociación Española Contra el Cáncer, European Innovation Council and SMEs Executive Agency (EISMEA). ⬇️ Swipe through the carousel to explore our milestones year by year ⬇️ #OneChainAnniversary #Innovation #Immunotherapy #OncologyResearch #CAR-T, #OneChain, #cellularimmunotherapies, #celltherapies, #leukaemia, #leukemia, #cancer, #biotech, #CARxALL, #Catalonia, #Spain